Idorsia Valuation Multiples

Idorsia Overview

About Idorsia

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Founded

2017

HQ

Employees

552

Website

idorsia.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $282M

EBITDA: ($88M)

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Idorsia Financials

Idorsia reported last 12-month revenue of $282M and negative EBITDA of ($88M).

In the same LTM period, Idorsia generated $254M in gross profit, ($88M) in EBITDA losses, and had net loss of ($141M).

Idorsia P&L

In the most recent fiscal year, Idorsia reported revenue of $282M and EBITDA of ($58M).

Idorsia expects next 12-month revenue of XXX and NTM EBITDA of XXX

Idorsia Stock Performance

Idorsia has current market cap of $1B, and enterprise value of $3B.

Idorsia's stock price is $4.75.

Idorsia Valuation Multiples

Idorsia trades at 9.6x EV/Revenue multiple, and (30.9x) EV/EBITDA.

Idorsia Financial Valuation Multiples

As of April 20, 2026, Idorsia has market cap of $1B and EV of $3B.

Equity research analysts estimate Idorsia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Idorsia has a P/E ratio of (8.6x).

Idorsia Margins & Growth Rates

Idorsia's revenue in the last 12 month grew by 12%.

Idorsia's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.7M for the same period.

Idorsia's rule of 40 is (18%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Idorsia's rule of X is (15%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Idorsia Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Idorsia M&A Activity

Idorsia acquired XXX companies to date.

Last acquisition by Idorsia was on XXXXXXXX, XXXXX. Idorsia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Idorsia Investment Activity

Idorsia invested in XXX companies to date.

Idorsia made its latest investment on XXXXXXXX, XXXXX. Idorsia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).